Filing summary: Helius Medical Technologies, Inc. — Form 10-Q
Identity note: The request metadata names Solana Co, but the supplied filing is for Helius Medical Technologies, Inc. (Nasdaq: HSDT). This summary reflects the supplied filing.
Business context and reporting period
The filing covers the quarter ended March 31, 2021, compared with the quarter ended March 31, 2020. Helius develops the PoNS non-invasive neurostimulation device. It was commercially available in Canada; U.S. commercialization was not expected before the first quarter of 2022. The FDA authorized the device on March 26, 2021 for short-term treatment of gait deficit associated with mild-to-moderate multiple sclerosis symptoms, as an adjunct to supervised therapeutic exercise for adults 22 and older.
Key financial metrics
Amounts below are in U.S. dollars; financial statement amounts are in thousands, except per-share data.
| Metric | Q1 2021 | Q1 2020 / comparison |
|---|---|---|
| Revenue | $84 | $207; down $123 |
| Gross profit | $69 | $106 |
| Gross margin | About 82% | About 51% |
| Research and development | $1,316 | $1,120 |
| Selling, general and administrative | $2,197 | $2,862 |
| Operating loss | $(3,501) | $(4,002) |
| Net loss | $(3,362) | $(4,757) |
| Basic and diluted loss per share | $(1.65) | $(5.38) |
| Cash used in operating activities | $(2,921) | $(3,751) |
| Cash, March 31 | $11,397 | $3,331 at December 31, 2020 |
| Working capital | $10,329 | $2,261 at December 31, 2020 |
| Total liabilities | $2,766 | $2,676 at December 31, 2020 |
Cash increased by $8.1 million in the quarter, principally from $11.0 million of net financing cash flow, including the February 2021 equity-and-warrant offering and warrant exercises. The filing reports no interest-bearing debt; liabilities shown include lease liabilities and deferred revenue. Operating expenses remained substantially above revenue, and the company continued to incur losses.
Material changes versus the prior comparable period
- Revenue decreased about 59%, primarily due to COVID-19 effects on Canadian sales and pricing changes intended to reduce upfront costs for clinics and patients. Q1 2021 included no fee revenue; license revenue was $7,000 in both periods.
- Operating loss improved by $501,000 and net loss by $1.4 million. Lower SG&A and amortization, plus a swing from a foreign-exchange loss of $765,000 to a gain of $139,000, contributed; R&D expense increased $196,000.
- Operating cash use declined by $830,000 year over year. The cash balance rose substantially following the February 2021 offering and warrant exercises.
- Shares outstanding rose from 1.48 million at December 31, 2020 to 2.31 million at March 31, 2021, reflecting financing and warrant exercises. The company completed a 1-for-35 reverse stock split effective December 31, 2020.
Outlook, risks, contingencies and unusual items
- Going concern: Management disclosed substantial doubt about the company’s ability to continue as a going concern within one year after filing. It estimated existing resources would fund operations into the first quarter of 2022 based on historical cash burn, but expects higher 2021 spending on U.S. pre-commercialization, manufacturing and staffing. Additional financing may be needed; availability and terms are uncertain.
- Commercial outlook: U.S. launch was expected in Q1 2022. The company was developing distribution, marketing and reimbursement plans. It anticipated that broad government and private-payer coverage could take at least 24 months; initial U.S. sales could rely mainly on self-pay patients.
- Reimbursement uncertainty: CMS delayed the Medicare Coverage of Innovative Technology rule’s effective date to December 15, 2021. Helius said it was assessing implications for its reimbursement strategy.
- Clinical and regulatory plans: The TBI-002 trial for traumatic brain injury remained temporarily suspended, with funding and timing under evaluation. The device remained under review in Australia; the company had withdrawn its EU application and planned to reconsider submission as conditions stabilized.
- COVID-19: Canadian clinics were operating at reduced capacity, affecting sales and patient engagement. The pandemic also risked delays to clinical programs, suppliers, regulatory work and U.S. launch preparations, as well as access to capital.
- Unusual/comparability items: Q1 2020 included a $174,000 intangible-asset impairment and a significant foreign-exchange loss; Q1 2021 included a foreign-exchange gain. These items affect period-to-period comparisons.
- The company reported no material pending legal proceedings and no off-balance-sheet arrangements known to management. Disclosure controls were deemed effective, and no material change in internal control over financial reporting was reported.
Important facts for investors to verify
- Confirm the filing issuer: the supplied document is Helius Medical Technologies, Inc., not Solana Co.
- Monitor cash burn, financing needs and progress against the stated runway into Q1 2022, particularly as launch-related spending rises.
- Track U.S. launch readiness, distribution, manufacturing capacity and the path to reimbursement following CMS’s delay.
- Assess whether Canadian clinic capacity and patient throughput recover, and whether pricing changes support sales growth without undermining margins.
- Follow the funding and timing decision for TBI-002 and any additional clinical or regulatory programs.